Krystal Biotech (KRYS) Retained Earnings (2016 - 2026)

Krystal Biotech has reported Retained Earnings for 11 years, with the latest figure at $1.2 billion in Q2 2026.

• Retained Earnings for Q2 2026 came in at $1.2 billion, up 7.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.2 billion (up 7.2% YoY), and the FY2025 annual result was $1.2 billion, up 5.95% from the prior year.
• Retained Earnings improved to $1.2 billion in Q2 2026, from $1.2 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $1.2 billion in Q2 2026 and troughed at $740.5 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Retained Earnings.
• The widest annual swing landed in 2022, when Retained Earnings jumped 50.02%; it then increased 4.82% in 2025.
• A 5-year view of Retained Earnings shows it stood at $803.7 million in 2022, then soared by 30.37% to $1.0 billion in 2023, then advanced by 7.58% to $1.1 billion in 2024, then gained by 5.95% to $1.2 billion in 2025, then advanced by 2.88% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $1.2 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.